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Editorial
Is recombinant FVIIa the magic bullet in the treatment of major bleeding?
Recombinant activated factor VII (rFVIIa) (NovoSeven1,
Novo Nordisk, Bagsvaerd, Denmark) was originally devel-
oped to treat bleeding in haemophiliacs with antibodies to
factor VIII and IX.1 2 At present, rFVIIa is approved in the
European Union for this indication and also for the treatment
of bleeding in FVII deficiency and Glanzmann throm-
basthenia refractory to platelet transfusions.
FVIIa normally circulates in minute quantities and binds
to tissue factor (TF) expressed by the damaged vascular bed.
The TF-FVIIa complex on TF-bearing cells activates FIX
and FX. FXa remains in close proximity to TF-bearing cells
and activates FV. The FXa–FVa complex on TF-bearing
cells rapidly converts small amounts of prothrombin into
thrombin.1 3 This initial small amount of thrombin activates
platelets, FVIII, FV and FXI. On the surface of activated
platelets, FVIIIa and FIXa gather to activate large quantities
of FX which finally (in conjunction with FVa) will result
in the large thrombin burst which enables the conversion
of fibrinogen to fibrin with initial clot formation. The
administration of exogenous rFVIIa accelerates the above
mechanism and in haemophiliacs with antibodies to factor
VIII and IX, rFVIIa may loosely bind to platelets and acti-
vate significant quantities of FX resulting in the thrombin
burst necessary for the transformation of fibrinogen to fibrin
with local clot formation.
It is tempting to speculate that exogenous rFVIIa,
by activating blood coagulation in the close vicinity of
TF-bearing cells, may help stop major bleeding in trauma
and surgery with absence of general thrombosis. Since the
initial spectacular case report in a young Israeli solder,4
a large number of case reports of successful use of rFVIIa
in patients with uncontrolled bleeding including trauma,
surgery, warfarin therapy and pregnancy have been pub-
lished.2 5–8 The problem with these reports is potential pub-
lication bias of positive cases, which, understandably,
editors are more likely to publish. Registries of similar
patient groups9 are also susceptible to submission and
publication bias of successful cases. Only recently, ‘non-
responders’7 and complications10 11 of rFVIIa treatment
have been described in bleeding patients. Faced with a
patient with uncontrolled bleeding the clinician is thus
left with significant uncertainty as to whether he or she is
obliged to use rFVIIa in an ‘off-label’ or ‘out-of-license’
indication or whether this could be withheld as there is little
published high level scientific evidence nor approval by any
health authority in Europe or the US. This dilemma is ampli-
fied by the fact that any decision in this scenario is often
associated with mortality, morbidity and high cost.
Bleeding is a major cause of mortality and morbidity
during the peri- and post-partum period. Several case reports
have described dramatic effects in patients suffering from
massive bleeding.2 4 5 7 8 In this issue of the Journal, Ahonen
and Jokela describe another series of life-threatening post-
partum bleeding in 12 patients treated with rFVIIa.12 The
authors report a partial or good response in 11 of their
12 patients to rFVIIa after a blood loss of between 5 and
15 litres. Despite such partial or good responses, 4 patients
had to undergo subsequent arterial embolization.12 Arterial
embolization, however, is not generally available on a 24 h
basis in all centres and its efficacy depends on the inter-
vential radiologist’s skill. Ideally, a randomized placebo-
controlled trial should be performed in patients with massive
blood loss associated with delivery. This is unlikely to
happen, owing to the rarity of the complication, the difficulty
in obtaining informed consent and the highly positive results
in already published cases and case series. In the report by
Ahonen and Kjokela, rFVIIa was used relatively late and
42% of patients had already had a hysterectomy. A number
of centres are now, based on anectodal reports, using rFVIIa
immediately before the decision to perform a hysterectomy
when arterial embolization is not available. Because of
the rapidity of the rFVIIa action, it is possible to wait and
observe the rFVIIa effect, if any, before proceeding to
hysterectomy.
There is scientific evidence that rFVIIa may be efficac-
ious in experimental trauma. Treatment with rFVIIA
(180 mg kg1) after grade V liver injury decreased blood
loss by nearly 50% in pigs.13 Even in pigs with coagulo-
pathy, with grade V liver injury, blood loss was reduced by
50% in rFVIIa (180 and 720 mg kg1) treated animals.14
Interestingly, rFVIIa (180 and 720 mg kg1) treatment
before puncturing a 2 mm hole into the aorta did not
decrease the initial blood loss but diminished significantly
re-bleeding during resuscitation, and rFVIIa treated animals
# The Board of Management and Trustees of the British Journal of Anaesthesia 2005. All rights reserved. For Permissions, please e-mail: journal.permissions@oupjournals.org
tolerated a higher blood pressure before re-bleeding.15
Patients suffering from major trauma may also benefit
from rFVIIa according to a recently completed prospective
randomized double-blind placebo-controlled multi-centre
study. In total, 301 patients with blunt or penetrating trauma
requiring transfusion of 8 units of red blood cells were
recruited.16 In this trial, three doses of rFVIIa were given:
200 mg kg1 at study entry, 100 mg kg1 at 1 h and another
100 mg kg1 at 3 h. In blunt trauma red blood cell trans-
fusions and the incidence of acute respiratory distress
syndrome (ARDS) were reduced and the incidence of
multi-organ failure tended to be reduced in patients with
penetrating trauma.16 Mortality, however, was equal in
the two groups.
So far, only two prospective randomized double-blind
placebo-controlled studies evaluating the efficacy of rFVIIa
in reducing blood loss and red blood cell transfusion needs in
surgery have been published.17 18 In 36 patients undergoing
open radical prostatectomy, relatively low doses of
20 mg kg1 and 40 mg kg1 of rFVIIa decreased periopera-
tive blood loss by more than 50% and allogeneic blood
transfusions were equally reduced.17 In contrast, in 204 non-
cirrhotic patients undergoing partial hepatectomy rFVIIa at
doses of 20 mg kg1 or 80 mg kg1 did not decrease peri-
operative blood loss and allogeneic blood transfusions.18
The study by Raobaikady and colleagues19 published in
this issue of the Journal is important since it represents
only the third prospective randomized double-blind
placebo-controlled study in this setting. The authors rando-
mized 48 patients undergoing major pelvic-acetabular
surgery to rFVIIa (90 mg kg1) or placebo. The primary
outcome variable was the total volume of perioperative
blood loss. In contrast to the study by Friederich and
colleagues,17 no reduction in perioperative blood loss or
allogeneic blood transfusion was observed.19 The only
difference was a slightly reduced postoperative blood loss
(240 ml vs 370 ml) in the rFVIIa-treated patients. Why were
these results so different, despite the fact that pre-defined
transfusion guidelines were used in both studies? First,
assessment of perioperative blood loss is notoriously
fraught with difficulties and imprecision. In addition, and
more importantly, the timing of the rFVIIa dosing was
different. In the study by Friederich and colleagues17 the
rFVIIa was given during the operation, just prior to the main
blood loss, whereas in the studies by Raobaikady and
colleagues19 and Lodge and colleagues,18 rFVIIa was
administered at skin incision. Given the rather short half
life of rFVIIa of approximately 2 h in bleeding patients,
dosing at skin incision might have been somewhat early
in operations with an average duration of 3 and 4 h.18 19
Alternatively, local blood coagulation could already be
maximally stimulated in patients undergoing orthopaedic
surgery without the addition of exogenous rFVIIa,
such that rFVIIa treatment cannot improve local blood
coagulation any further, at least not in patients without
compromised blood coagulation. For now, rFVIIa is not
indicated for routine use prior to high bleeding risk elective
surgery.
More recently, another ‘off-label’ use of rFVIIa has been
reported in patients with acute intracerebral haemorrhage
but without an underlying coagulopathy.20 The further
increase in the volume of the intracranial bleeding was
diminished by rFVIIa (40, 80 and 160 mg kg1) treatment
by 50% and the neurological outcome at 3 months was
improved. Mortality tended to be lower in rFVIIa-treated
patients. However, thromboembolic events tended to be
more frequent in rFVIIa-treated patients. This is not a
surprise as these are patients with a normal coagulation
system who may have artherosclerotic plaques exposing
TF-bearing cells to the blood.21 This may well be the basis
for rFVIIa-activated local blood coagulation and eventual
thrombosis.
Recombinant VIIa is a drug that is easy and quick to
mix and administer. It is generally well tolerated with
thrombosis being the primary adverse effect of concern to
clinicians. Although initially thromboses were rare since
the drug was used in patients with severe coagulopathies,
more recently more thromboses have been reported as
the drug was used prophylactically in surgery or in patients
without a coagulopathy such as in cerebral bleeding
referred to above. Aledort calculated that the risk of
rFVIIa-related thrombosis is 25 per 105 infusions.11 In pub-
lished placebo-controlled studies, however, the risk of
thrombosis was not statistically different between patient
and control groups.
So, where do we stand in May 2005? Are we obliged to
give rFVIIa to patients with major bleeding to avoid accusa-
tion of substandard treatment or is rFVIIa treatment not
indicated, owing to the lack of high level scientific evidence,
lack of approval by any health authority, the potential of
serious side-effects and its high cost? No definitive answers
can be given at present. However, the following issues
should be on the research agenda in the near future for
this interesting drug. First, the clinical scenario, outside
congenital bleeding disorders, where rFVIIa is beneficial
needs to be defined. In terms of trauma, the trauma trial
discussed above,16 once published in a peer-reviewed jour-
nal, may provide further information. Second, the optimal
timing and dose, which are largely unknown, need to be
ascertained. Third, the most appropriate co-treatment with
conventional blood products,22 the minimum levels of coa-
gulation factors and platelets required and also the minimum
pH and temperature for the optimal efficacy of rFVIIa need
to be determined. Fourth, laboratory monitoring of the effi-
cacy of rFVIIa treatment will be helpful. The effect on
prothrombin time is particularly marked but this does not
always translate to clinically improved blood coagulation.
Similarly measurement of the level of factor VII in plasma
does not correlate with clinical efficacy. Two promising
monitoring techniques are thrombelastography13 and the
endogenous thrombin potential measured in platelet rich
plasma.23
Editorial
554
Last but not least, we should keep in mind that the current
treatment guidelines for the severely bleeding patient of the
Committee on Trauma of the American College of Surgeons
in their ATLS1 program (www.facs.org) simply aim at ‘stop
the bleeding’.24 This may be achieved using different
strategies, be it a proper surgical source control, emboliza-
tion, the use of coagulation enhancing drugs or any combi-
nation thereof.
In conclusion, rFVIIa is certainly a highly potent sub-
stance capable of locally promoting blood coagulation
under certain circumstances. However, its clinical efficacy
outside the setting of congenital coagulation disorders
remains to be defined. Whilst nobody should be accused
of providing substandard care when opting not to give
rFVIIa for major bleeding, a trial of rFVIIa when conven-
tional surgical, interventional and blood product support
measures have failed is certainly worth a try.
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